Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1152Prostatic Neoplasms 642Neoplasms 581Carcinoma, Non-Small-Cell Lung 488Multiple Myeloma 483Leukemia, Myeloid, Acute 461Leukemia 418Lung Neoplasms 399Lymphoma 381Leukemia, Lymphocytic, Chronic, B-Cell 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Lymphoma, Non-Hodgkin 326Colorectal Neoplasms 310Pancreatic Neoplasms 306Neoplasm Metastasis 302Myelodysplastic Syndromes 301Melanoma 286Hodgkin Disease 253Head and Neck Neoplasms 249Brain Neoplasms 231Lymphoma, Follicular 224Ovarian Neoplasms 221Recurrence 220Glioblastoma 215Lymphoma, Mantle-Cell 211Lymphoma, Large B-Cell, Diffuse 209Squamous Cell Carcinoma of Head and Neck 176Colonic Neoplasms 162Carcinoma, Renal Cell 158Carcinoma, Hepatocellular 154

Interventions

ublituximab 1LFB-R603 1Interferon beta-1a 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × Optic Neuritis × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT00179478 2017-09-06

CHAMPIONS10

Beth Israel Deaconess Medical Center

Phase 4 Completed
155 enrolled 10 charts

Cerebellar Diseases, Multiple Sclerosis, Myelitis, Transverse, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡